scholarly journals HIIT is not superior to MICT in altering blood lipids: a systematic review and meta-analysis

2019 ◽  
Vol 5 (1) ◽  
pp. e000647 ◽  
Author(s):  
Gina Wood ◽  
Anna Murrell ◽  
Tom van der Touw ◽  
Neil Smart
Keyword(s):  
Systematic Review ◽  
Athletic Training ◽  
Meta Analysis ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Moderate Intensity ◽  
Continuous Training ◽  
Intervention Component ◽  
Post Intervention ◽  
Eligibility Criteria

ObjectiveTo compare the effects of moderate intensity continuous training (MICT) and high intensity interval training (HIIT) on adult lipid profiles; to identify training or participant characteristics that may determine exercise-induced change in total cholesterol (TC), triglycerides (TRG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C).DesignSystematic review and meta-analysis.Data sourcesEnglish language searches of several databases were conducted from inception until September 2019.Eligibility criteria for excluding studiesInclusion: (1) published randomised controlled human trials with group population n≥5; (2) intervention duration ≥4 weeks; (3) comparing HIIT with MICT; and (4) reporting pre–post intervention lipid measurements. Exclusion: subjects with chronic disease, <18 years, pregnant/lactating, in elite athletic training; and studies with a dietary or pharmaceutical intervention component.ResultsTwenty-nine data sets (mmol/L) of 823 participants were pooled and analysed. Neither HIIT nor MICT was better in decreasing TC (0.10 (−0.06 to 0.19), p=0.12, I2=0%), TRG (−0.05 (−0.11 to 0.01), p=0.10, I2=0%), LDL-C (0.05 (−0.06 to 0.17), p=0.37, I2=0%), or TC/HDL-C (−0.03 (−0.36 to 0.29), p=0.85, I2=0%). HIIT significantly raised HDL-C (0.07 (0.04 to 0.11), p<0.0001, I2=0%) compared with MICT.ConclusionNeither HIIT nor MICT is superior for altering TC, TRG, or LDL-C, or TC-HDL-C ratio. Compared with MICT, HIIT appeared to significantly improve HDL-C. Clinicians may prescribe either protocol to encourage participation in exercise and reduce cardiovascular risk. To raise HDL-C, HIIT may result in a larger effect size compared with MICT.PROSPERO registration numberCRD42019136722.

scholarly journals Sulforaphane ameliorates lipid profile in rodents: an updated systematic review and meta-analysis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kaili Du ◽  
Yuxin Fan ◽  
Dan Li
Keyword(s):  
Systematic Review ◽  
Weight Control ◽  
Weighted Mean Difference ◽  
Meta Analysis ◽  
Low Density Lipoprotein ◽  
Disease Model ◽  
Density Lipoprotein ◽  
Liver Weight ◽  
Lipoprotein Cholesterol ◽  
Alcoholic Fatty Liver

AbstractSulforaphane (SFN), a naturally-occurring isothiocyanate enriched in cabbage and broccoli, has been provided as food supplements to improve weight management and reduce lipid levels. However, its effects on serum lipid profiles are contradictory. In this review, a meta-analysis and systematic review of SFN on lipid reduction and weight control is assessed with mice and rats fed on high-fat diet. The effects of SFN supplementation were evaluated by weighted mean difference (WMD) in body weight (BW), liver weight (LW) and also by its effect on serum lipids. A random-effects model was applied to estimate the overall summary effect. SFN reduced BW (WMD: − 2.76 g, 95% CI: − 4.19, − 1.34) and LW (WMD: − 0.93 g, 95% CI: − 1.63, − 0.23) significantly in our ten trials. Its effects on serum total cholesterol (TC) (WMD: − 15.62 mg/dL, 95% CI: − 24.07, − 7.18), low-density lipoprotein cholesterol (LDL-C) (WMD: − 8.35 mg/dL, 95% CI: − 15.47, − 1.24) and triglyceride (TG) (WMD: − 40.85 mg/dL, 95% CI: − 67.46, − 14.24) were significant except for high-density lipoprotein cholesterol (HDL-C) component (WMD: 1.05 mg/dL, 95% CI: − 3.44, 5.54). However, species, disease model, duration, SFN dosage as well as route of administration did not explain the heterogeneity among studies. In summary, these findings provide new insights concerning preclinical strategies for treating diseases including obesity, diabetes, hypertension, non-alcoholic fatty liver disease as well as cardiovascular disease with SFN supplements.

scholarly journals Potential Biomarkers for Post-Stroke Cognitive Impairment: A Systematic Review and Meta-Analysis

2022 ◽  
Vol 23 (2) ◽  
pp. 602
Author(s):  
Ka Young Kim ◽  
Ki Young Shin ◽  
Keun-A Chang
Keyword(s):  
Systematic Review ◽  
Uric Acid ◽  
Cognitive Impairment ◽  
Meta Analysis ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Cochrane Library ◽  
Blood Proteins ◽  
Post Stroke

Stroke is a primary debilitating disease in adults, occurring in 15 million individuals each year and causing high mortality and disability rates. The latest estimate revealed that stroke is currently the second leading cause of death worldwide. Post-stroke cognitive impairment (PSCI), one of the major complications after stroke, is frequently underdiagnosed. However, stroke has been reported to increase the risk of cognitive impairment by at least five to eight times. In recent decades, peripheral blood molecular biomarkers for stroke have emerged as diagnostic, prognostic, and therapeutic targets. In this study, we aimed to evaluate some blood-derived proteins for stroke, especially related to brain damage and cognitive impairments, by conducting a systematic review and meta-analysis and discussing the possibility of these proteins as biomarkers for PSCI. Articles published before 26 July 2021 were searched in PubMed, Embase, the Web of Science, and the Cochrane Library to identify all relevant studies reporting blood biomarkers in patients with stroke. Among 1820 articles, 40 were finally identified for this study. We meta-analyzed eight peripheral biomarker candidates: homocysteine (Hcy), high-density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), uric acid, and glycated hemoglobin (HbA1c). The Hcy, CRP, TC, and LDL-C levels were significantly higher in patients with PSCI than in the non-PSCI group; however, the HDL-C, TG, uric acid, and HbA1c levels were not different between the two groups. Based on our findings, we suggest the Hcy, CRP, TC, and LDL-C as possible biomarkers in patients with post-stroke cognitive impairment. Thus, certain blood proteins could be suggested as effective biomarkers for PSCI.

scholarly journals Effectiveness of Salvia Officinalis on Mediation of Serum Lipid in Clinical Trials: Systematic Review and Meta-analysis (P12-004-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Sepideh Alasvand ◽  
WIlliam Bridges ◽  
Vivian Haley-Zitlin
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Chronic Disease ◽  
Serum Lipid ◽  
Animal Studies ◽  
Serum Lipids ◽  
Meta Analysis ◽  
Density Lipoprotein ◽  
Salvia Officinalis ◽  
Lipoprotein Cholesterol

Abstract Objectives The present systematic review and meta-analysis investigates the effectiveness of S. officinalis leaves in management of dyslipidemia of chronic disease. Dyslipidemia is one of the main indicators of cardiovascular disease (CVD). It is typically characterized by elevated levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL) and triglyceride (TG) along with reduction of high-density lipoprotein cholesterol (HDL) in blood. The handling of dyslipidemia is a crucial factor in the general control of the cardiovascular risk in individuals suffering from diseases such as diabetes, CVD or hypertension. Plant foods have played an important role in chronic disease management. S. officinalis leaves (sage) have been identified as improving glucose homeostasis and serum lipids in animal and human models. Methods PubMed, FSTA, Web of Science, CINAHEL and MEDLINE databases were searched using keywords (“Serum lipids” OR triglyceride* OR cholesterol* OR “LDL” OR “HDL” OR dyslipidemia) AND (sage or "Salvia officinalis") up to January 2019. Review articles, animal studies, non-trial, non-specific related plants, and articles which did not examine lipid profiles were included in the exclusion criteria. Articles that met the inclusion criteria included effects of administration of Salvia officinalis on serum lipid in clinical trials. All statistical calculations were performed using SAS software version 9.2 (SAS, Cary NC, USA). Results From 243 studies, four of the trials met the selection criteria of the meta-analysis. Salvia officinalis significantly improved serum lipids. The estimated value for TC was −52.64 mg/dl, 95% CI: −71.0505 to −34.23, P = 0.0001 and LDL −23.28 mg/dl, 95% CI: −40.07 to −6.48, P = 0.006. Moreover, TG was −74.98 mg/dl, 95% CI: −129.16 to −20.8190, P = 0.006 and HDL-C at 6.3424 mg/dl, 95% CI: 1.58 to 11.1033, P = 0.009) was significantly improved after Salvia officinalis administration Conclusions Although the systematic review and meta-analysis investigation involved few studies it revealed promising efficiency of Salvia officinalis on improving the serum lipids in clinical trials and suggested that Salvia officinalis can be an appropriate plant food to manage dyslipidemia of chronic diseases. Funding Sources N/A.

Sign in / Sign up

Export Citation Format

Share Document